News coverage about Dermira (NASDAQ:DERM) has trended somewhat negative on Thursday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dermira earned a media sentiment score of -0.05 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.7103159748672 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Where the Dermira, Inc. (DERM) Stock Knocks 52-week High? (thestocksnews.com)
- Earnings per share (EPS) in the Limelight – Dermira (NASDAQ:DERM) (thestockgem.com)
- Dermira, Inc. (DERM) predicted -6.00% EPS growth for next year (wallstreetinvestorplace.com)
- Updates on Most Active Stock: Dermira Inc Cm ST (DERM) and First Bancorp (FBP) (postregistrar.com)
- Cantor Fitzgerald Reaffirms “Buy” Rating for Dermira (DERM) (americanbankingnews.com)
NASDAQ:DERM traded up $0.05 on Thursday, hitting $7.99. 651,946 shares of the company’s stock were exchanged, compared to its average volume of 1,605,585. The company has a debt-to-equity ratio of 1.87, a current ratio of 5.28 and a quick ratio of 5.28. Dermira has a 52 week low of $7.78 and a 52 week high of $35.76. The stock has a market capitalization of $330.81, a PE ratio of -1.09 and a beta of 0.86.
DERM has been the topic of several research reports. BidaskClub raised shares of Dermira from a “hold” rating to a “buy” rating in a research report on Tuesday, January 30th. Cantor Fitzgerald set a $45.00 price objective on shares of Dermira and gave the company a “buy” rating in a research report on Monday, January 15th. Guggenheim reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Dermira in a research report on Thursday, December 14th. Mizuho cut their price objective on shares of Dermira from $43.00 to $39.00 and set a “buy” rating on the stock in a research report on Tuesday, December 12th. Finally, Cowen set a $25.00 price objective on shares of Dermira and gave the company a “buy” rating in a research report on Monday, March 5th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $32.71.
In other Dermira news, SVP Christopher M. Griffith sold 18,458 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total transaction of $499,288.90. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $27.07, for a total transaction of $81,210.00. Following the sale, the insider now directly owns 5,802 shares in the company, valued at $157,060.14. The disclosure for this sale can be found here. Insiders have sold a total of 26,758 shares of company stock worth $728,459 over the last three months. Insiders own 13.30% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Dermira (NASDAQ:DERM) Receives Media Sentiment Score of -0.05” was originally posted by BBNS and is the sole property of of BBNS. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://baseballnewssource.com/2018/03/30/somewhat-critical-news-coverage-somewhat-unlikely-to-impact-dermira-derm-share-price/1973512.html.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.